EUVIMEDEUVIMED entdecken
Crossref

Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways

Nibrass Taher Abdali iD, Yasmin S Mohamed, Hala F Zaki, Laila A A Ramadan, Hassan Afify iD

The Prostate · 2025-11 · 85 (15) · 1412-1423

DOI: 10.1002/pros.70026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 31.07.2025. Verfasst von Nibrass Taher Abdali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, Al-Farahidi University, Baghdad, Iraq. Hauptthemen laut MEDLINE: Eugenol, Prostatic Hyperplasia, Uric Acid, Probenecid. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benign prostatic hyperplasia (BPH) is a prevalent condition among aging males, significantly impacting their quality of life. Emerging evidence links elevated uric acid (UA) levels to prostatic inflammation and hyperplasia, potentially through oxidative stress and activation of proliferative pathways. However, the role of UA in BPH pathogenesis remains poorly defined. The study aims to investigate the potential protective effects of a natural phenolic compound, eugenol, and/or probenecid against testosterone‐BPH in rats, along with the possible underlying mechanisms.

Methods

BPH was induced by administering testosterone (3 mg/kg; s.c.) for 2 weeks, either alone or following a 1‐week pretreatment with probenecid (200 mg/kg/day; i.p.), eugenol (10 mg/kg/day; p.o.), or their combination.

Results

The results demonstrated a significant increase in prostate index, cell survival markers such as cyclin D1 expression, and histopathological features indicative of BPH following testosterone administration. Furthermore, testosterone led to elevated uric acid levels, oxidative stress, inflammatory markers, and activation of pro‐survival pathways including PI3‐K/Akt/mTOR and NFκB. However, treatment with probenecid, eugenol, or their combination effectively attenuated these alterations, demonstrating their anti‐inflammatory, antioxidative, and anti‐hyperproliferative effects. Notably, combination therapy exhibited superior efficacy compared to individual treatments. These findings suggest that probenecid and eugenol may mitigate testosterone‐induced BPH by targeting the uric acid‐induced inflammation and pro‐survival pathways.

Conclusions

This study provides novel insights into the therapeutic potential of probenecid and eugenol as adjunctive treatments for BPH, offering promising avenues for further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EugenolProstatic HyperplasiaUric AcidProbenecidMaleAnimalsTestosteroneRatsInflammationOxidative StressRats, Sprague-DawleySignal TransductionProstateCell Survival

Stichwörter der Autor:innen

benign prostatic hyperplasiaeugenolinflammationprobenecidtestosterone

Substanzen

EugenolUric AcidTestosteroneProbenecid

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Pharmacy, Al-Farahidi University, Baghdad, Iraq.
  • Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.

ORCID-Profile: Nibrass Taher Abdali, Hassan Afify

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Abdali, N. T., Mohamed, Y. S., Zaki, H. F., Ramadan, L. A. A., & Afify, H. (2025). Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways. The Prostate, 85(15), 1412-1423. https://doi.org/10.1002/pros.70026

Vancouver

Abdali NT, Mohamed YS, Zaki HF, Ramadan LAA, Afify H. Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways. The Prostate. 2025;85(15):1412-1423. doi:10.1002/pros.70026

BibTeX
@article{Abdali2025,
  author = {Abdali, Nibrass Taher and Mohamed, Yasmin S and Zaki, Hala F and Ramadan, Laila A A and Afify, Hassan},
  title = {Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways},
  journal = {The Prostate},
  year = {2025},
  volume = {85},
  number = {15},
  pages = {1412--1423},
  doi = {10.1002/pros.70026}
}
Kostenlos starten →